Imaging PD-L1 in Tumors Using a Radioactive Probe in Solid Cancers
Tests a radioactive PD-L1 imaging probe to detect the protein in solid tumors.
Plain-language title generated from the registry record
Registry title: Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Where in China
- Beijing Cancer HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University Cancer Hospital & Institute
- Trial code
- NCT07848243
- Record updated
- 29 September 2026
- Original description
[18F]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumorsRead full original descriptionShow less
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
[18F]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors
Inclusion: Age >18 years old, ECOG score 0 or 1; subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors; There was at least one measurable target lesion according to RECIST1.1 criteria; Predicted survival time ≥12 weeks; Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements; Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period; Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.
Exclusion: Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation; Claustrophobia or other mental illness; Severe abnormal liver and kidney function; Pre-pregnancy, pregnant and lactating women; Unable to lie flat for half an hour; Refusal to be a clinical investigator.